-- ラーセン＆トゥブロ（NSE:LT、BOM:500510）の建築・工場事業部門は、インド証券取引所への木曜日の提出書類によると、非公開の不動産顧客から、インドの3州にまたがる3つのプロジェクトに関する3件の「大型」受注を獲得した。 同社は、大型受注を250億インドルピーから500億インドルピーの受注と定義している。 1件目の受注は、ハイデラバードにおける住宅開発プロジェクトで、地下2階、地上55階建ての高層住宅タワー10棟とクラブハウス2棟の設計・建設が含まれる。 また、ムンバイにおける高級高層住宅タワー（地下5階、地上63階建て）の建設も受注した。 3件目の受注は、カルナータカ州におけるプロジェクトで、複数の住宅ヴィラ、高級ホテル、および付帯施設の建設に関するものである。
Related Articles
Research
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Arch Capital Group Ltd.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month targe price to $115 from ($118), valuing ACGL shares at 10.9x our '27 operating EPS estimate of $10.55 (lowered today by $0.40) and at 11.6x our '26 EPS estimate of $9.93 (cut by $0.12), versus the shares' three-year average forward multiple and the peer average of 12x. ACGL posted Q1 operating EPS of $2.50 vs. $1.54 the prior year, beating the $2.46 consensus but missing our $2.62 estimate. However, operating revenues declined 1.3% Y/Y, significantly below our 8%-15% growth forecast, reflecting 4.8% lower earned premiums partly offset by 8% higher investment income. We view ACGL as a top-tier underwriter with superior underwriting capabilities, maintaining strong profitability metrics despite competitive headwinds. We now see revenue growth of 3%-5% in 2026 and 2027. Underlying underwriting results remained superior to industry averages, with the combined ratio at 82.3% vs. 81.0% the prior year, about 5-10 points better than industry, which will support EPS.
$ACGL
Research
Research Alert: Shell: Q1 2026 Net Profit Meets Consensus View; Guides For Lower Gas Output
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shell's Q1 2026 adjusted net profit of USD6.9B (+24% Y/Y) was within market expectations but above our forecast, doubling sequentially from USD3.3B in Q4 2025 due to volatile energy markets from the Middle East conflict that caused Brent crude to reach USD81/bbl (+27% from Q4). We have reservations about the sustainability of these results given the exceptional trading conditions rather than operational improvements, with broad-based earnings led by Chemicals & Products swinging to USD1.9B profit from a USD66M loss as refinery utilization surged to 99%. Q2 2026 guidance signals significant disruptions, with Integrated Gas production forecast to be down 30%-36% and LNG volumes declining 9%-14% due to conflict impacts, including on its Qatar operations. Balance sheet deteriorated materially, with net debt rising to USD52.6B and gearing to 23%, while a USD11.2B working capital outflow, including USD6.7B inventory increases, raises concerns about potential reversals if commodity prices normalize, in our view.
$SHEL
Research
Research Alert: CFRA Raises Rating On Shares Of Cvs Health Corporation To Buy From Hold
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $100 from $80, 13.5x our 2026 EPS estimate (raised to $7.40 from $7.17; 2027 estimate up to $8.26 from $8.18), above CVS's three-year and five-year average forward multiples of 9.7x and 10.3x, respectively. While headwinds remain for CVS's insurance operations (Aetna) within a challenging medical cost environment, CVS is executing well within its longer-term turnaround strategy with indications of margin improvement, in our view. We also see debt levels declining from recent highs following two major acquisitions in 2023. Although the Pharmacy & Consumer Wellness segment's adjusted operating income declined 8.8% Y/Y to $1.20B during Q1, we see this as the result of seasonal impacts (less severe flu season) and look favorably on CVS raising segment adjusted operating income guidance for 2026 by 1.5%'given stronger performance expectations for the rest of the year. Shares yield 3.1%. We upgrade our rating to Buy from Hold.
$CVS